ImpediMed wins “Life Changing Technology” award
Tuesday, 12 June, 2012
UniQuest start-up and now ASX-listed company, ImpediMed Limited (ASX:IPD), has been internationally recognised for making “the biggest difference on an individual while addressing the greatest medical need” for its diagnostic technology, bioelectrical impedance analysis (BIA).
UniQuest patented the BIA technology for detecting and monitoring of lymphoedema in 1999 and founded ImpediMed Limited in 2000.
The BIA technology underpins ImpediMed’s L-DexTM U400 limb application for lymphoedema, which was developed by The University of Queensland’s (UQ) Dr Leigh Ward and the Queensland University of Technology’s (QUT) Dr Brian Thomas and Dr Bruce Cornish.
The “Life Changing Technology” award was presented by the San Diego-based BIOCOM, the largest regional life science association in the world, at its 6th Annual Medical Device & Diagnostics Expo.
UniQuest Managing Director, David Henderson, said the award highlighted the impact of Australian research on cancer patient care around the world.
“We congratulate ImpediMed and the researchers on receiving such an important accolade. To have a panel of judges representing global companies like Johnson & Johnson and Sharp Healthcare acknowledge ImpediMed in this way is a significant endorsement of Australian university-based innovation.”
Hormone therapy shifts body proteins to match gender identity
Researchers have discovered that gender-affirming hormone therapy can alter body proteins to...
Targeting 'molecular bodyguards' weakens prostate cancer cells
Research reveals that two enzymes — PDIA1 and PDIA5 — act as 'molecular...
Females found to carry a higher genetic risk of depression
An international team of scientists has discovered about twice as many genetic 'flags'...
